TNF-alpha Inhibition in CRPS: A Randomized Controlled Trial
WithdrawnNot applicableNCT02031211
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Studying the effects of Etanercept (an anti-Tumor Necrosis Factor alpha) on early Chronic Regional Pain Syndrome (CRPS). Our hypothesis is that Etanercept will improve patient symptoms if given in early CRPS.
Study details
- Official title
- Etanercept for the Treatment of Chronic Regional Pain Syndrome
- Conditions
- Crps
- Chronic Regional Pain Syndrome
- Interventions
- Drug: Etanercept
- Drug: Placebo
- Sponsor
- Stanford University
- Start date
- 2014-06
- Primary completion
- 2016-10
- Sex
- Female
- Age range
- from 10 Years to 17 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1. Female pediatric Chronic Regional Pain Syndrome (CRPS) patients with unilateral CRPS of the lower extremity, ages 10-17 years of age. 2. Patients must meet CRPS Type I diagnostic criteria and have current evidence of edema, and a temperature difference between the affected and contralateral limb ≥1.0°C. 3. Duration of symptoms less than 4 months. Exclusion Criteria: 1. Active malignancy or history of malignancy. 2. Active infection. 3. History of Tuberculosis (TB) or TB exposure. 4. Pregnancy. 5. Concomitant disease causing immunocompromise. 6. Concomitant autoimmune disease such as rheumatoid arthritis, psoriasis, ankylosing spondylitis or Crohn's Disease. 7. Poorly controlled psychiatric disease including anxiety, depression or attention deficit hyperactivity disorder. 8. Hepatic or renal impairment as indicated by serum transaminases and/or creatinine ≥ 150% normal value for age. 9. Evidence of or history of demyelinating disease.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02031211